Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Immune checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway are a paradigm-shifting cancer therapy.
Programmed cell death ligand 2
(
PD-L2
) is another ligand of PD-1, but its prognostic significance in solid cancer patients after surgery remains controversial. In this study, we aimed to reveal the prognostic implication of
PD-L2
in solid tumors through a meta-analysis.
Methods:
We searched PubMed, Embase and the Cochrane library for studies reporting the relationship between
PD-L2
expression and prognosis or clinicopathological features in solid cancer patients after surgery from inception to January 2018, with language restricted to English. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were determined to explore the prognostic value of
PD-L2
expression. Odds ratios (ORs) were also calculated to investigate the relationship between
PD-L2
expression and clinicopathological parameters.
Results:
Sixteen studies incorporating 3,533 patients were included in our meta-analysis. The pooled results revealed that
PD-L2
overexpression was a weak negative predictor for overall survival (OS; HR = 1.38, 95% CI = 1.05-1.81,
P
= 0.021), as well as a strong predictor for poor disease-free survival (DFS)/progression-free survival (PFS) (HR = 1.44, 95% CI = 1.15-1.81,
P
= 0.001). In subgroup analyses, high
PD-L2
expression revealed an unfavorable prognostic prediction for OS in
hepatocellular carcinoma
(
HCC
) (HR = 1.60, 95% CI = 1.12-2.29,
P
= 0.011) and for DFS/PFS in
HCC
(HR = 1.50, 95%CI = 1.04-2.16,
P
= 0.031) as well as clear cell renal cell carcinoma (HR = 1.45, 95% CI = 1.03-2.03,
P
= 0.033). Moreover,
PD-L2
expression implied a weak trend toward the presence of lymphatic metastasis (presence vs. absence, OR = 1.61, 95% CI = 0.98-2.65,
P
= 0.061).
Conclusion:
High
PD-L2
expression may promote tumor metastasis and predict unfavorable prognosis in solid cancer patients after surgery, especially in
HCC
.
...
PMID:Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis. 3089 23
